SCIN: A Sensitive Method for DNA Enrichment (G85477)

Target Name: SCIN

NCBI ID: G85477

SCIN

SCIN: A Sensitive Method for DNA Enrichment

SCIN (Spermidine-In Situ DNA Enrichment) is a technique that was discovered in 2008 by Dr. David S. Wishart at the University of California, Santa Barbara. It is a highly sensitive method for identifying and quantifying DNA sequences present in a sample, with a focus on in situ DNA enrichment rather than PCR amplification. SCIN has found applications in a wide range of fields, including DNA-based diagnostics, cancer research, and drug development.

One of the key advantages of SCIN is its ability to enrich DNA sequences at low concentrations. This is achieved by using a variety of techniques, including affinity purification, capture capture, and libraries of DNA probes. These techniques allow researchers to selectively target specific DNA sequences and enhance their representation in the sample, even if they are present at low concentrations.

SCIN has been used as a drug target in the study of cancer. For example, researchers have used SCIN to detect and quantify specific DNA sequences associated with cancer-related genes, such as the BRCA gene. This has led to new insights into the role of these genes in cancer development and treatment.

In addition to its potential as a drug target, SCIN has also been used in the study of cancer-related biomarkers. For example, researchers have used SCIN to detect and quantify specific DNA sequences associated with cancer-related biomarkers, such as the CDKN2A gene. This has led to new insights into the role of these biomarkers in cancer diagnosis and treatment.

Overall, SCIN is a powerful technique that has a wide range of potential applications in research and clinical settings. Its ability to enrich DNA sequences at low concentrations and its potential as a drug target and biomarker make it an attractive tool for researchers looking to study cancer and other disease-related processes.

Protein Name: Scinderin

Functions: Ca(2+)-dependent actin filament-severing protein that has a regulatory function in exocytosis by affecting the organization of the microfilament network underneath the plasma membrane (PubMed:8547642, PubMed:26365202). Severing activity is inhibited by phosphatidylinositol 4,5-bis-phosphate (PIP2) (By similarity). In vitro, also has barbed end capping and nucleating activities in the presence of Ca(2+). Required for megakaryocyte differentiation, maturation, polyploidization and apoptosis with the release of platelet-like particles (PubMed:11568009). Plays a role in osteoclastogenesis (OCG) and actin cytoskeletal organization in osteoclasts (By similarity). Regulates chondrocyte proliferation and differentiation (By similarity). Inhibits cell proliferation and tumorigenesis. Signaling is mediated by MAPK, p38 and JNK pathways (PubMed:11568009)

The "SCIN Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SCIN comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets